BioWorld covered Nexo's emergence from stealth, its $60 million financing and the company's ambition to translate chemistry and chemical biology into programs against elusive cancer targets.
The preview also linked the launch to Nexo’s research collaboration with MD Anderson and presented the financing as the foundation for moving difficult oncology programs into a more disciplined discovery and development path.
BioWorld reported on Nexo’s emergence from stealth with $60 million in Series A financing and centered its story on the company’s attempt to translate chemistry and chemical biology into programs against elusive cancer targets. The piece framed the company name itself as a reflection of the connections Nexo is trying to create across science, biotech and translational development.
Original coverage: BioWorld